Literature DB >> 16705661

Neuropsychological deficits in Parkinson's disease patients with visual hallucinations.

Blanca Ramírez-Ruiz1, Carme Junqué, María-José Martí, Francesc Valldeoriola, Eduardo Tolosa.   

Abstract

Recent neuropathological and neuroimaging studies suggest the involvement of several temporal regions in Parkinson's disease (PD) patients with visual hallucinations (VH). We examined 24 nondemented PD patients with VH, 21 PD patients without VH, and 21 healthy controls using a battery of tests assessing different aspects of temporal lobe function. PD patients with VH showed poorer performance in language, verbal learning, semantic fluency, and visuoperceptive functions compared to controls and PD patients without VH. Differences in verbal learning and visuoperceptive functions were independent of general cognitive status, disease severity, and depression. We suggest that a wide range of neuropsychological deficits can contribute to the emergence of VH in PD. (c) 2006 Movement Disorder Society.

Entities:  

Mesh:

Year:  2006        PMID: 16705661     DOI: 10.1002/mds.20965

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Authors:  Daniel Collerton; John-Paul Taylor
Journal:  Future Neurol       Date:  2013-07

2.  Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis.

Authors:  Jared T Hinkle; Kate Perepezko; Catherine C Bakker; Ted M Dawson; Vanessa Johnson; Zoltan Mari; Cherie L Marvel; Kelly A Mills; Alexander Pantelyat; Olga Pletnikova; Liana S Rosenthal; Melissa D Shepard; Daniel A Stevens; Juan C Troncoso; Jiangxia Wang; Gregory M Pontone
Journal:  Int J Geriatr Psychiatry       Date:  2017-05-16       Impact factor: 3.485

Review 3.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 4.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

5.  Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.

Authors:  Jin-Song Yang; Xiao-Hong Wu; Hao-Gang Yu; Li-Song Teng
Journal:  Inflammopharmacology       Date:  2017-06-02       Impact factor: 4.473

6.  Treatment of psychosis and dementia in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

7.  Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia.

Authors:  Naroa Ibarretxe-Bilbao; Blanca Ramírez-Ruiz; Eduardo Tolosa; María Jose Martí; Francesc Valldeoriola; Nuria Bargalló; Carme Junqué
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

8.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 9.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

Review 10.  Episodic recognition memory and the hippocampus in Parkinson's disease: A review.

Authors:  Tanusree Das; Jaclyn J Hwang; Kathleen L Poston
Journal:  Cortex       Date:  2018-12-04       Impact factor: 4.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.